Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
$1.07
+3.9%
$0.96
$0.61
$25.47
$18.27M-0.141.08 million shs642,565 shs
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.00
$0.00
$0.00
$0.45
$3K3.9485 shs16 shs
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$2.30
-16.1%
$2.65
$1.72
$15.70
$2.78M0.21229,503 shs74,087 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$3.24
+6.1%
$2.84
$1.75
$9.37
$5.23M1.66845,309 shs77,763 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
+4.39%-8.55%+42.46%-1.83%-95.35%
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%+237.50%+350.00%-73.00%-98.88%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-16.06%-25.57%+2.22%-27.44%-58.53%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
+6.07%-8.62%+72.07%+21.62%+2,049.50%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.0737 of 5 stars
0.02.00.00.00.00.00.6
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.0738 of 5 stars
0.02.00.00.00.00.00.6
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.2634 of 5 stars
0.05.00.00.00.00.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.00
N/AN/AN/A
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00
N/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.00
N/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/A($559.39) per shareN/A
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/A$4.04 per shareN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$4.83M0.57N/AN/A$5.12 per share0.45
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$13.97M0.37N/AN/A$3.01 per share1.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-$11.90MN/A0.00N/AN/AN/A-369.67%-100.06%5/13/2025 (Estimated)
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
-$8.63M-$11.01N/AN/AN/AN/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-$7.68M-$13.75N/AN/A-163.75%-90.74%-71.70%5/13/2025 (Estimated)
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$4.84M-$4.02N/AN/AN/A-26.82%-68.98%-26.39%6/16/2025 (Estimated)

Latest SNOA, ALLR, AMPE, and INM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025N/A
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-$8.10N/AN/AN/AN/AN/A
2/12/2025Q2 2025
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/A-$3.64N/A-$3.64N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/AN/A
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/A
2.75
2.75
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.09
3.05
2.44
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
3.34
2.49

Institutional Ownership

CompanyInstitutional Ownership
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
11.53%
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
5.73%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
20.12%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
1017.08 million4.43 millionNot Optionable
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
201.14 million1.10 millionNo Data
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
101.21 million711,000Not Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.62 million1.55 millionNot Optionable

Recent News About These Companies

Sonoma Pharmaceuticals expands into UK market
Sonoma Pharmaceuticals, Inc. (O8Z.F)
Sonoma Pharmaceuticals announces relaunch of dermatology, eye care lines

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Allarity Therapeutics stock logo

Allarity Therapeutics NASDAQ:ALLR

$1.07 +0.04 (+3.88%)
Closing price 05/8/2025 04:00 PM Eastern
Extended Trading
$1.11 +0.04 (+3.74%)
As of 06:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Ampio Pharmaceuticals stock logo

Ampio Pharmaceuticals NYSE:AMPE

$0.0027 0.00 (0.00%)
As of 05/7/2025

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

InMed Pharmaceuticals stock logo

InMed Pharmaceuticals NASDAQ:INM

$2.30 -0.44 (-16.06%)
Closing price 05/8/2025 03:59 PM Eastern
Extended Trading
$2.26 -0.04 (-1.96%)
As of 06:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$3.24 +0.19 (+6.07%)
Closing price 05/8/2025 03:57 PM Eastern
Extended Trading
$3.14 -0.09 (-2.78%)
As of 06:21 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.